Moderna exec tells of company’s pursuit of COVID vaccine
Moderna didn’t expect to go to market with its new vaccine technology for several years when 2020 began, the company’s CFO said in a recent talk, but that changed after the technology Moderna spent almost a decade developing helped fast-forward development for COVID-19 vaccines. More than 1,000 people watched a virtual discussion on Feb. 17 Read More →
Read More →Arcutis shares flat on earnings report
Arcutis Biotherapeutics saw a steep rise in operating expenses resulting in a 183% increase in net loss compared to the previous year when the company revealed its fourth quarter and full-year financial results on Feb. 16. However, the Westlake Village biotech company is still in high spirits, as the company is in a “strong financial Read More →
Read More →Conejo Valley braces for Amgen layoffs
Biotech giant Amgen is in the process of laying off hundreds of workers, including as many as 100 at its Thousand Oaks headquarters. According to a spokesperson for the company, approximately 500 workers will be let go beginning April 2, with fewer than 20% of those workers located in Thousand Oaks. Amgen employs around 22,000 Read More →
Read More →Amgen to lay off hundreds, including in Thousand Oaks
Biotech giant Amgen is in the process of laying off hundreds of workers, including as many as 100 at its Thousand Oaks headquarters. According to a spokesperson for the company, approximately 500 workers will be let go beginning April 2. Less than 20% of those workers are located in Thousand Oaks. Amgen employs around 22,000 Read More →
Read More →
Amgen shares slip after projections of flat 2021 sales
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen reports rising revenue, warns of flat 2021
Amgen, one of the world’s largest biotech companies, saw rising revenue in the fourth quarter of 2020, but the COVID-19 pandemic could dampen the outlook for the company and its investors in 2021, according to earnings released Feb. 2. The Thousand Oaks-based biotech firm had $6.6 billion in revenue in the fourth quarter, a 7% Read More →
Read More →Arcutis stock soars on drug trial news; company announces $150M capital raise
Stock of Arcutis Biotherapeutics, a Westlake Village-based company developing dermatological treatments, shot up more than 30% on Feb. 1 after the company released positive results from a recent clinical trial. Later in the day, Arcutis said it plans to sell $150 million worth of its common stock. Before stock trading opened, the company announced positive Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
